Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$23,229,501.04
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2010 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2 Nakanishi, Nobuki Burnham Institute
Systematic analysis of neural circuitry in mouse models of autism Osten, Pavel Cold Spring Harbor Laboratory
Role of L-type calcium channels in hippocampal neuronal network activity Owen, Scott Stanford University
Novel probiotic therapies for autism Patterson, Paul California Institute of Technology
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Pedersen, Cort University of North Carolina at Chapel Hill
Small-molecule compounds for treating autism spectrum disorders Philpot, Ben The University of North Carolina at Chapel Hill
Neurogenetic model of social behavior heterogeneity in autism spectrum disorders Platt, Michael Duke University
High-resolution diffusion tensor imaging in mouse models relevant to autism Poptani, Harish University of Pennsylvania
Novel genetic animal models of autism Powell, Craig University of Texas Southwestern Medical Center
Neuroligin function in vivo: Implications for autism and mental retardation Powell, Craig University of Texas Southwestern Medical Center
Animal models of autism: Pathogenesis and treatment Powell, Craig University of Texas Southwestern Medical Center
Genetic models of serotonin transporter regulation linked to mental disorders Ramamoorthy, Sammanda Medical University of South Carolina
Role of a novel Wnt pathway in autism spectrum disorders Reichardt, Louis University of California, San Francisco
A novel cell-based assay for autism research and drug discovery Restifo, Linda University of Arizona
Caspr2 dysfunction in autism spectrum disorders Robbins, Elissa Yale University
Novel strategies to manipulate Ube3a expression for the treatment of autism and Angelman syndrome Roth, Bryan University of North Carolina at Chapel Hill
Methods for production of ICSI and SCNT derived macaque stem cells Schatten, Gerald Southwest Foundation For Biomedical Research
Optimization of methods for production of both ICSI- and SCNT derived baboon embryonic stem cells Schatten, Gerald Southwest Foundation For Biomedical Research
Micro-RNA regulation in pluripotent stem cells Schatten, Gerald Southwest Foundation For Biomedical Research
Dissecting the neural control of social attachment Shah, Nirao University of California, San Francisco
Mice lacking Shank postsynaptic scaffolds as an animal model of autism Sheng, Morgan Massachusetts Institute of Technology
Using zebrafish and chemical screening to define function of autism genes Sive, Hazel Whitehead Institute for Biomedical Research
Characterization of autism susceptibility genes on chromosome 15q11-13 Smith, Stephen Beth Israel Deaconess Medical Center
Identifying impairments in synaptic connectivity in mouse models of ASD Speed, Haley University of Texas Southwestern Medical Center
Function and dysfunction of neuroligins Sudhof, Thomas Stanford University

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.